

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4619025

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MOUNTAIN VIEW PHARMACEUTICALS, INC.	07/20/2015
RECEIVING PARTY DATA	
Name:	CREALTA PHARMACEUTICALS LLC
Street Address:	500 W. SILVER SPRING DR.
Internal Address:	SUITE K-200
City:	GLENDALE
State/Country:	WISCONSIN
Postal Code:	53217
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14806494
CORRESPONDENCE DATA	
Fax Number:	(617)395-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6173957000
Email:	WZpatents@lalaw.com
Correspondent Name:	LANDO & ANASTASI LLP
Address Line 1:	ONE MAIN STREET
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02142
ATTORNEY DOCKET NUMBER:	C2163-700323
NAME OF SUBMITTER:	WEI ZHANG
SIGNATURE:	/Wei Zhang/
DATE SIGNED:	09/29/2017
Total Attachments: 4	
source=2613981_1#page1.tif	
source=2613981_1#page2.tif	
source=2613981_1#page3.tif	
source=2613981_1#page4.tif	

Exhibit C

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("Assignment") is made and entered into by and between **Mountain View Pharmaceuticals, Inc.**, a California corporation having its principal offices at 3475 Edison Way, Suite S, Menlo Park, CA, USA 94025 ("Assignor"), and **Crealta Pharmaceuticals LLC**, a Delaware limited liability company having its principal offices at 500 W. Silver Spring Dr., Suite K-200, Glendale, WI, USA 53217 ("Assignee").

WHEREAS, Assignor and Assignee are parties to a Fourth Amendment to License Agreement By and Among Mountain View Pharmaceuticals, Inc., Duke University, and Crealta Pharmaceuticals LLC, including Patent Assignment, dated as of July 20, 2015 (the "Amendment"); and

WHEREAS, pursuant to the Amendment, Assignor wishes to assign to Assignee, and Assignee wishes to acquire from Assignor, the patents and patent applications set forth on Schedule A attached hereto, including any substitutes, continuations, divisions, reissues reexaminations or extensions thereof, and including the subject matter of all claims thereof (collectively, the "Assigned Patent Rights").

NOW, THEREFORE, for good and valuable consideration, Assignor does hereby sell, assign, transfer and set over to Assignee, subject to the terms of the Amendment, Assignor's right, title and interest in and to the Assigned Patent Rights, for the United States, including, without limitation, all corresponding rights that are or may be secured under the laws of the United States, now or hereafter in effect, for Assignee's use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, including, without limitation, all claims for damages by reason of infringement occurring on or after the Modification Effective Date as defined in the Amendment or other unauthorized use of the Assigned Patent Rights occurring on or after the Modification Effective Date, with the right to sue for, and collect the same for Assignee's use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives.

Assignor hereby permits the Commissioner for Patents to record Assignee as an assignee and owner of the Assigned Patent Rights.

**REMAINDER OF PAGE INTENTIONALLY BLANK;
SIGNATURE PAGE FOLLOWS.**

MRD

MOUNTAIN VIEW PHARMACEUTICALS, INC.

By: Merry R. Sherman

Name: Merry R. Sherman, Ph.D.

Title: CEO and President

CREALTA PHARMACEUTICALS LLC

By: E.A. Dosover

Name: E.A. Dosover

Title: General Counsel

Schedule A

Schedule A-1

TITLE: PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

INVENTORS: L. David Williams of Fremont, CA; Michael S. Hershfield of Durham, NC; Susan J. Kelly of Chapel Hill, NC; Mark G.P. Saifer of San Carlos, CA; Merry R. Sherman of San Carlos, CA

ASSIGNEES: Mountain View Pharmaceuticals, Inc. and Duke University

Application No.	Date Filed	Publication No.	Patent No.	Date Issued or Published	Status
09/370,084	06-Aug-1999		6,576,235 B1	10-Jun-2003	Issued
09/839,946	19-Apr-2001	US-2003- 0166249-A1	7,723,089 B2	25-May-2010	Issued
11/833,590	03-Aug-2007	US-2008- 0031864-A1	7,927,589 B2	19-Apr-2011	Issued
12/769,570	28-Apr-2010	US-2010- 0323422-A1	8,067,553 B2	29-Nov-2011	Issued
12/769,572	28-Apr-2010	US-2010- 0323423-A1		23-Dec-2010	Pending
13/083,152	08-Apr-2011	US-2013- 0052677-A1	8,618,267 B2	31-Dec-2013	Issued
13/306,336	29-Nov-2011	US-2012- 0149083-A1		14-Jun-2012	Pending

Schedule A-2

TITLE: AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-
IMMUNOGENIC POLYMER CONJUGATES
or
*METHOD FOR PURIFYING URATE OXIDASE TETRAMERS AND OCTAMERS

INVENTORS: Merry R. Sherman of San Carlos, CA; Mark G.P. Saifer of San Carlos, CA; L. David
Williams of Fremont, CA; Michael S. Hershfield of Durham, NC; Susan J. Kelly of
Chapel Hill, NC

ASSIGNEES: Mountain View Pharmaceuticals, Inc. and Duke University

Application No.	Date Filed	Publication No.	Patent No.	Date Issued or Published	Status
09/501,730	10-Feb-2000		6,783,965 B1	31-Aug-2004	Issued
11/882,750	3-Aug-2007	US-2008- 0057048-A1	7,927,852 B2	19-Apr-2011	Issued
13/085,793	13-Apr-2011	US-2011- 0287466-A1	8,921,064 B2*	30-Dec-2014	Issued
14/462,368	18-Aug-2014	US-2014- 0363414-A1		11-Dec-2014	Pending